| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total net cash provided by investing activities | 7,127 | -31,237 |
| Loans repaid | - | 0 |
| Repurchase and retirement of common stock | 732 | 371 |
| Total net cash used in financing activities | -732 | -371 |
| Effect of exchange rate changes on cash and cash equivalents | 43 | 39 |
| Increase (decrease) in cash and cash equivalents | -2,241 | -38,623 |
| Cash and cash equivalents at beginning of period | 54,420 | - |
| Cash and cash equivalents at end of period | 52,179 | - |
ORAMED PHARMACEUTICALS INC. (ORMP)
ORAMED PHARMACEUTICALS INC. (ORMP)